Nuklearmedicinsk diagnostik og cancerpræcisionsmedicin

Annika Loft; Andreas Kjær

Nuklearmedicinsk diagnostik og cancerpræcisionsmedicin

Institut for Klinisk Medicin

Abstract

Cancer therapy has taken a major leap forward in recent years. However, to fully unfold the concept of precision medicine, non-invasive methods for characterisation of tumours and metastases are needed. PET imaging offers this. Whereas 18F-fluorodeoxyglucose-PET is currently used in most cancer types for diagnosing or staging, we expect new tracers to become available in the clinical routine, supporting tailoring and monitoring of cancer therapies.

Bidragets oversatte titel	Nuclear medical diagnostic and cancer precision medicine
Originalsprog	Dansk
Artikelnummer	V06180463
Tidsskrift	Ugeskrift for Laeger
Vol/bind	180
Udgave nummer	46
Antal sider	4
ISSN	0041-5782
Status	Udgivet - 2018

FN’s Verdensmål

Dette resultat bidrager til følgende verdensmål

Adgang til dokumentet

http://ugeskriftet.dk/videnskab/nuklearmedicinsk-diagnostik-og-cancerpraecisionsmedicin

Citationsformater

@article{12313b40c58446d3b0691e584db4b65b,

title = "Nuklearmedicinsk diagnostik og cancerpr{\ae}cisionsmedicin",

abstract = "Cancer therapy has taken a major leap forward in recent years. However, to fully unfold the concept of precision medicine, non-invasive methods for characterisation of tumours and metastases are needed. PET imaging offers this. Whereas 18F-fluorodeoxyglucose-PET is currently used in most cancer types for diagnosing or staging, we expect new tracers to become available in the clinical routine, supporting tailoring and monitoring of cancer therapies.",

author = "Annika Loft and Andreas Kj{\ae}r",

year = "2018",

language = "Dansk",

volume = "180",

journal = "Ugeskrift for Laeger",

issn = "0041-5782",

publisher = "Almindelige Danske Laegeforening",

number = "46",

}

TY - JOUR

T1 - Nuklearmedicinsk diagnostik og cancerpræcisionsmedicin

AU - Loft, Annika

AU - Kjær, Andreas

PY - 2018

Y1 - 2018

N2 - Cancer therapy has taken a major leap forward in recent years. However, to fully unfold the concept of precision medicine, non-invasive methods for characterisation of tumours and metastases are needed. PET imaging offers this. Whereas 18F-fluorodeoxyglucose-PET is currently used in most cancer types for diagnosing or staging, we expect new tracers to become available in the clinical routine, supporting tailoring and monitoring of cancer therapies.

AB - Cancer therapy has taken a major leap forward in recent years. However, to fully unfold the concept of precision medicine, non-invasive methods for characterisation of tumours and metastases are needed. PET imaging offers this. Whereas 18F-fluorodeoxyglucose-PET is currently used in most cancer types for diagnosing or staging, we expect new tracers to become available in the clinical routine, supporting tailoring and monitoring of cancer therapies.

M3 - Tidsskriftartikel

C2 - 30417816

SN - 0041-5782

VL - 180

JO - Ugeskrift for Laeger

JF - Ugeskrift for Laeger

IS - 46

M1 - V06180463

ER -

Nuklearmedicinsk diagnostik og cancerpræcisionsmedicin

Abstract

FN’s Verdensmål

Adgang til dokumentet

Fingeraftryk

Citationsformater